Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer

3 Dec 2024

Abstract excerpt

Neuroendocrine prostate cancer (NEPC), an aggressive and lethal subtype of prostate cancer (PCa), often arises as a resistance mechanism in patients undergoing hormone therapy for prostate adenocarcinoma. NEPC is associated with a significantly poor prognosis and shorter overall survival compared to conventional prostate adenocarcinoma due to its aggressive nature and limited response to standard of care...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Prostate Cancer Treatment and Research
Share to Protein Degradation and Inhibitors
Share to Radiopharmaceutical Chemistry and Applications

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39682746
DOI: 10.3390/cells13231999

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 19 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate CancerPMID 39682746Read ↗

Role of MicroRNAs in Neuroendocrine Prostate CancerSemantic proximity Read ↗

Targeting Key Players of Neuroendocrine Differentiation in Prostate CancerSemantic proximity Read ↗

Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiationSemantic proximity Read ↗

Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancerSemantic proximity Read ↗

Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.Semantic proximity Read ↗

Molecular model for neuroendocrine prostate cancer progressionSemantic proximity Read ↗

The Many Faces of Neuroendocrine Differentiation in Prostate Cancer ProgressionSemantic proximity Read ↗

Cellular plasticity and the neuroendocrine phenotype in prostate cancer.Semantic proximity Read ↗

Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancerSemantic proximity Read ↗

Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targetsSemantic proximity Read ↗

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.Semantic proximity Read ↗

Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.